Therapeutic utility of aspirin in the <it>Apc</it><sup><it>Min</it>/+</sup> murine model of colon carcinogenesis
Zhang Xiao-Jing, Reuter Brian K, Miller Mark JS
BMC Cancer · 2002
doi:10.1186/1471-2407-2-19 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>In recent years it has become evident that nonsteroidal anti-inflammatory drugs, in particular aspirin represent a potential class of cancer chemotherapeutic agents. Despite the wealth of knowledge gained from epidemiological, clinical and animal studies, the effectiveness of aspirin to treat established gastrointestinal cancer has not been determined. The present study examines the ability of aspirin to treat established polyposis in <it>Min</it>/+ mice.</p> <p>Methods</p> <p><it>Min</it>/+ mice with established polyposis were treated orally once daily from 12–16 weeks of age with either drug vehicle or aspirin (25 mg/kg). Upon completion of treatment, the number, location and size of intestinal tumours was determined. Additional variables examined were the number of apoptotic cells within tumours and COX activity.</p> <p>Results</p> <p>Administration of aspirin for 4 weeks to <it>Min</it>/+ mice produce no effect on tumour number compared to vehicle-treated <it>Min</it>/+ mice (65 ± 8 vs. 63 ± 9, respectively). In addition, aspirin had no effect on tumour size or location. However, aspirin treatment produced a greater than 2-fold (p < 0.05) increase in the number of apoptotic positive cells within tumours and significantly decreased hepatic PGE<sub>2</sub> content.</p> <p>Conclusions</p> <p>Aspirin was found to have no effect on tumour number and size when administered to <it>Min</it>/+ mice with established polyposis. The findings in the present study call in to question the utility of aspirin as a stand-alone treatment for established GI cancer. However, aspirin's ability to significantly promote apoptosis may render it suitable for use in combinatorial chemotherapy.</p>
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.